The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) Research Group assessed night vision in a cohort of 1,052 CAPT patients.

A new study of age-related macular degeneration (AMD), a disease that affects more than nine million Americans, will pave the way for the biopharmaceutical industry to develop better treatments and cures, according to the Foundation Fighting Blindness, which partially funded the research.

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is “unacceptable” concludes the July issue of Drug and Therapeutics Bulletin (DTB).